A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

Date: May 2, 2022 Issue #:  1649Summary:  The FDA has approvedSusvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz), a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research